Zetta Genomics is a genomic data technology company and spin-out from the University of Cambridge and Genomics England, led by founder and CEO Ignacio Medina. The company leverages genomic and big data expertise to deliver XetaBase, a data management platform that empowers clinicians to make faster and more accurate diagnoses at scale. Zetta plans to use the funding to expand its presence and build strategic partnerships with industry leaders including Microsoft, Fujitsu and IQVIA. The latest financing is an extension of its second Seed round, reflecting continued investor support. Headquartered in Cambridge, UK, the company is focused on scaling and innovating its technologies while enhancing customer focus. Zetta Genomics builds XetaBase, a genomic data management platform that simplifies tertiary genomic data analysis by aggregating, indexing, and enriching secondary data at scale and speed. The company raised £1.9M in a Second Seed funding round to accelerate growth of XetaBase and expand operations. Proceeds will be used to grow the platform toward managing 500,000 genomes, configure customer success capabilities, deepen bioinformatics and translation expertise, and build out engineering capabilities. Zetta says the funding positions it for a Series A in 2024. Founded in 2017 and led by CEO Mark Bailey, Zetta is a spin-out from the University of Cambridge and Genomics England. The company is based in Cambridge, UK, and has an international office in Valencia, Spain. It plans international growth with an initial focus on the UK, US, and Spain.

Total raised

$5M

Funding rounds

2

Latest round

Seed

Latest activity

Feb 2024